125 related articles for article (PubMed ID: 21278576)
61. Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review.
Ho SC; Chong HY; Chaiyakunapruk N; Tangiisuran B; Jacob SA
J Affect Disord; 2016 Mar; 193():1-10. PubMed ID: 26748881
[TBL] [Abstract][Full Text] [Related]
62. The relationship between average daily dose, medication adherence, and health-care costs among diabetic peripheral neuropathic pain patients initiated on duloxetine therapy.
Chen SY; Wu N; Boulanger L; Fraser KA; Zhao Y
Pain Pract; 2010; 10(6):530-9. PubMed ID: 20412505
[TBL] [Abstract][Full Text] [Related]
63. Continuity of outpatient treatment after discharge of patients with major depressive disorder.
Wang HR; Song HR; Jung YE; Woo YS; Jun TY; Kim KS; Bahk WM
J Nerv Ment Dis; 2013 Jun; 201(6):519-24. PubMed ID: 23686160
[TBL] [Abstract][Full Text] [Related]
64. Duloxetine may enhance control of pain related to bladder trauma.
Hsu CC; Ku SC; Chang HA; Kao YC; Tzeng NS
Aust N Z J Psychiatry; 2014 Sep; 48(9):881. PubMed ID: 24651062
[No Abstract] [Full Text] [Related]
65. Duloxetine-induced life-threatening long QT syndrome.
Štuhec M
Wien Klin Wochenschr; 2013 Mar; 125(5-6):165-6. PubMed ID: 23440523
[No Abstract] [Full Text] [Related]
66. Predictors of duloxetine adherence and persistence in patients with fibromyalgia.
Cui Z; Zhao Y; Novick D; Faries D
J Pain Res; 2012; 5():193-201. PubMed ID: 22792005
[TBL] [Abstract][Full Text] [Related]
67. Duloxetine fights major depressive disorder.
Wimett L; Laustsen G
Nurse Pract; 2005 Mar; 30(3):6-7. PubMed ID: 15753808
[No Abstract] [Full Text] [Related]
68. Increases in amplitude of low-frequency fluctuations in left fronto-parietal area after duloxetine therapy in first-episode, drug-naïve, major depressive disorder with panic disorder patients.
Lai CH
J Neuropsychiatry Clin Neurosci; 2012; 24(3):E24-5. PubMed ID: 23037667
[No Abstract] [Full Text] [Related]
69. Effectiveness and tolerability of duloxetine in 2 different ethnic samples: a prospective observational cohort study.
Collazos F; Ramos M; Qureshi A; Eiroa-Orosa FJ; Rodriguez A; Castells X; Ribases M; Valero S; Casas M
J Clin Psychopharmacol; 2013 Apr; 33(2):254-6. PubMed ID: 23422381
[No Abstract] [Full Text] [Related]
70. Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs.
Ivanova JI; Birnbaum HG; Kantor E; Schiller M; Swindle RW
Pain Med; 2014 Jun; 15(6):1015-26. PubMed ID: 24529260
[TBL] [Abstract][Full Text] [Related]
71. Duloxetine-induced subcortical growth in a patient with major depressive disorder and panic disorder.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E42-3. PubMed ID: 21677225
[No Abstract] [Full Text] [Related]
72. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report.
Einarson A; Smart K; Vial T; Diav-Citrin O; Yates L; Stephens S; Pistelli A; Kennedy D; Taylor T; Panchaud A; Malm H; Koren G; Einarson TR
J Clin Psychiatry; 2012 Nov; 73(11):1471. PubMed ID: 23218163
[No Abstract] [Full Text] [Related]
73. Therapeutic adherence in primary care depressed patients: a longitudinal study.
Serrano MJ; Vives M; Mateu C; Vicens C; Molina R; Puebla-Guedea M; Gili M
Actas Esp Psiquiatr; 2014; 42(3):91-8. PubMed ID: 24844808
[TBL] [Abstract][Full Text] [Related]
74. Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia.
Zhao Y; Sun P; Bernauer M
J Pain Res; 2012; 5():443-51. PubMed ID: 23152695
[TBL] [Abstract][Full Text] [Related]
75. Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment.
Chen SY; Hansen RA; Farley JF; Gaynes BN; Morrissey JP; Maciejewski ML
Psychiatr Serv; 2010 Jan; 61(1):81-5. PubMed ID: 20044424
[TBL] [Abstract][Full Text] [Related]
76. Measurement-based care in psychiatric practice: a policy framework for implementation.
Harding KJ; Rush AJ; Arbuckle M; Trivedi MH; Pincus HA
J Clin Psychiatry; 2011 Aug; 72(8):1136-43. PubMed ID: 21295000
[TBL] [Abstract][Full Text] [Related]
77. Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.
Peng X; Sun P; Novick D; Andrews J; Sun S
J Pain Res; 2014; 7():37-46. PubMed ID: 24470771
[TBL] [Abstract][Full Text] [Related]
78. Increased anterior cingulate regional homogeneity after duloxetine therapy in first-episode, drug-naïve, major depressive disorder with panic disorder patients: a case series.
Lai CH
J Neuropsychiatry Clin Neurosci; 2012; 24(3):E13-4. PubMed ID: 23037661
[No Abstract] [Full Text] [Related]
79. Influence of combinations of drugs that act on the CYP2D6 metabolic pathway in the treatment of major depressive disorder: a population-based study.
Sicras-Mainar A; Guijarro P; Armada B; Blanca-Tamayo M; Navarro-Artieda R
Eur Psychiatry; 2014 Aug; 29(6):331-7. PubMed ID: 24332870
[TBL] [Abstract][Full Text] [Related]
80. Duloxetine treatment adherence across mental health and chronic pain conditions.
Able SL; Cui Z; Shen W
Clinicoecon Outcomes Res; 2014; 6():75-81. PubMed ID: 24596469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
